An Efficient Way for Glycosylation of Spirostanol

Shu Jie HOU, Chuan Chun ZOU, Ping Sheng LEI*, De Quan YU

Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100050

Abstract: Using thioglycosides as donors, trimethylsilyl trifluoromethanesulfonate (TMSOTf) and N-iodosuccinimide(NIS) as promoter, a modified procedure for the glycosylation of spirostanol was developed. A series of saponins were synthesized in mild condition with excellent yields.

Keywords: Spirostanol glycoside, glycosylation, trimethylsilyl trifluoromethanesulfonate, ethyl 1-thioglycoside, N-iodosuccinimide.

Spirostanol glycosides are naturally occurring glycosides and as active constituents in many well-known herbal medicinal plants¹. Some of them have been shown to be antidiabetic², antitumor³, antitussive⁴, and platelet aggregation inhibitor⁵. Structurally, the sugar moiety was attached to the 3 position of the aglycone through 1, 2–trans glycosidic bond.

To synthesize steroidal saponins, many 2-acetyl sugars had been used as donors for the glycosylation of the aglycone⁶. However, because of acetyl migration and ortho ester formaion, those reactions gave the corresponding saponins in low to moderate yields. Many researchers have reported various methods for this purpose with high yields⁷⁻¹¹. Here we report our work for the glycosylation of steroid.

Thioglycosides were often used as donors in the synthesis of oligosaccharides. Biao Yu and co-workers had used 1-thioglycosides as one of donors to extend the sugar chain of diosgenin saponins *via* 'one-pot' manner ¹².

We turned the monosaccharides into corresponding protected ethyl 1-thioglycosides by the method reported before¹³. Using the thioglycosides as dononrs, three different spirostanols tigogenin **1**, diosgenin **2** and hecogenin **3**, were glycosylated in excellent yields. The coupling result was shown in **Table 1**. During the process of the glycosylation for the three spirostanols, no acyl transfer products or ortho esters had been found. All the structures of the products were confirmed by ¹H-NMR and the spectra data proved that the glycosidic bonds between the sugar moiety and aglycone were exclusively 1, 2-trans.

Myszka¹⁴ employed N-tetracholorophthaloyl protected D-glucosamine bromide promoted by AgOTf to couple with diosgenin giving the product **2d** in moderate yield. In

.

^{*} E-mail : lei@imm.ac.cn

Entry Donors Acceptors Products $\delta_{\rm H}(ppm)$ $J_{1,2}(Hz)$ Yield 1 1a 5.44 8.7 92% 1 2a15 2 2 5.46 8.7 Quantitative a 3 3 3a 5.45 8.7 Quantitative 91% 4 1 1b 4.90 7.5 5 2 2b 4.90 8.1 93% 6 3 3b 4.88 7.5 Quantitative 7 1 **1c** 5.15 1.8 95% 2 8 2c5.16 1.8 95% 92% 9 3 **3c** 5.16 1.5 $2d^{14}$ 10 d 2 5.47 8.4 93% $2e^{16}$ 2 11 4.89 7.9 95% 92% 12 f 1 1f 4.84 8.1

Table 1 Glycosylation of spirostanol

the present glycosylation procedure, the yield of the corresponding product **2d** was 93%. Using N-phthaloyl protected D-glucosamine bromide, Zou¹⁵ got the protected diosgenin saponin **2a** in the yield of 82%. Applying 1-thioglycoside as donor, we got the product **2a** quantitatively. Deng¹⁶ applied NIS-AgOTf as promoter to couple a 1-thioglucoside with diosgenin offering the product **2e** in the yield of 55%. With our glycosylation procedure, the yield of **2e** was 95%. This reaction was successfully scaled up to the preparation of tigogenyl-2-deoxy-2-phthalimido-3,4,6-tri-*O*-acetyl-β-D-glucopyranoside in excellent yield, which was the key intermediate for our parallel synthesis of tigogenyl glycosides.

General procedure for glycosylation

1 eq. of sapogenin, from 1.2 to 1.5 eq. of ethyl 1-thioglycoside was dissolved in anhydrous dichloromethane, powdered 4 Å molecular sieves was added and the reaction mixture was stirred at room temperature under argon for 30 min. At -15 $^{\circ}$ C 1.5 eq. NIS in dichloromethane was added, 15 min later 0.2 eq TMSOTf was injected into the mixture. When TLC showed the reaction was completed, a few drops of Et₃N were added, diluted with dichloromethane, filtered through celite and concentrated in vacuum. The residue was chromatographed on silica gel (petroleum ether/ ethyl acetate =10:1-4:1) giving white amorphous powder.

Figure 1 Selected donors and acceptors

Acceptors:

Donors:

Acknowledgment

Financial support of this research from the National Natural Science Foundation of China (20372085) is gratefully acknowledged by the authors.

References and Notes

- G. R. Waller, K. Yamasaki, Saponins Used in Taditional and Modern Medicine, Plenum Press: New York, 1996.
- 2. N. Nakashima, I. Kimura, M. Kimura, H. Matsuura, J. Nat. Prod., 1993, 56, 345.
- R.T.Wu, H. C. Chiang, W. C. Fu., K. Y. Chien, L. Y. Horng, *Inter. J. Immunopharmacol.*, 1990,12,777.
- 4. T. Miyata, J. Trad. Sino-Jpn. Med., 1992, 13, 276.
- 5. J. X. Dong, G. Y. Han, Planta Medica, 1991, 57, 460.

- (a). L. N. Atopkina, N. L. Uvarova, G. B. Elyakov, *Carbohydr. Res.*, 1997, 303, 449. (b). S. Pikul, A. G. Switzer, *Tetrahedron: Asymmetry*, 1997, 8, 1165. (c). F. G. Urban, B. S. Moore, R. Breitenbach, *Tetrahedron Lett.*, 1990, 31, 4421
- 7. C. C. Zou, S. J. Hou, P. S. Lei, X. T. Liang, Chin. Chem. Lett., 2003, 14(3), 229.
- 8. S. Deng, B. Yu, J. Xie, Y. Hui, J., Org. Chem., **1999**, 64, 7265.
- 9. C. Zou, S. Hou, S. Yang, P. Lei, X. Liang, Carbohydr. Res., 2003, 338, 721.
- 10. J. Sun, X. Han, B. Yu, Carbohydr. Res., 2003, 338, 827.
- 11. M. Lahmnn, H. Gyback, P. J. Garegg, et al., Carbohydr. Res., 2002, 337, 2153.
- (a). B. Yu, H. Yu, Y. Z. Hui, X. W. Han, Tetrahedron Lett., 1999, 40, 8591.
 (b). H. Yu, B. Yu, X. Y. Wu, Y. Z. Hui, X. W. Han, J. Chem. Soc., Perkin Trans., 2000, 1, 1445.
- 13. Z. akulski, D. Pierozynski, A. Zamojski, Tetrahedron, 1994, 50, 2975.
- 14. D. Bednarczyk, W. Kaca, H. Myszka, et al., Carbohydr.Res., 2000, 328, 249.
- 15. C. Zou, S. Hou, P. Lei, X. Liang, Chin. Chem. Lett., 2003, 14, 229.
- 16. S. Deng, B. Yu, Y. Hui, H. Yu, X. Han, Carbohydr. Res., 1999, 317, 53.
 - Selected spectral data of synthesized new compounds: $\textbf{1a}. \ ^{1}\text{H-NMR} \ (CDCl_{3}, \, \delta_{ppm}), \, 7.87-7.75 \ (m, \, 4H, \, NthPh), \, 5.81 (dd, \, 1H, \, J_{3', \, 4'} \, 9.0, \quad J_{2', \, 3'} \, 10.5 \ Hz,$ H-3), 5.44(d, 1H, J_{1', 2'} 8.7 Hz, H-1), 5.12 (dd, 1H, J_{3', 4'} 9.0, J_{4', 5'} 9.0 Hz, H-4), 4.35(m, 1H, H-16), 4.25(m, 1H, H-2), 4.15 (m, 2H, H-6), 3.85(m, 1H, H-5), 3.50-3.26 (m, 3H, H-3 and H-26), 2.10, 2.02, 1.85 (3s, 9H, COCH₃), 0.94 (d,3H, J 6.6 Hz), 0.78 (d,3H, J 5.7 Hz), 0.71 (s, 3H), 0.66 (s, 3H). ${f 1b}$: ${}^1{\mbox{H-NMR}}$ (CDCl₃, δ_{ppm}), 8.11-7.21 (m, 20H, H-OBz), 5.96(d, 1H, $J_{3',4'}$ 3.3 Hz H-4), 5.75 (dd, 1H, $J_{1',2'}$ 7.5, $J_{2',3'}$ 10.5 Hz, H-2'), 5.57(dd, 1H, $J_{2',3'}$ 10.5, $J_{3',4'}$ 3.3 Hz , H-3'), 4.90 (d, 1H, $J_{1',2'}$ 7.5 Hz, H-1), 4.66 (dd, 1H, $J_{5',6'a}$ 6.9, $J_{5',6'b}$ 6.9 Hz, H-5), 4.47 (m, 2H, H-6), 4.30 (m, 1H, H-16), 3.61-3.44 (m, 3H, H-3 and H-26), 1.05 (d, 3H, J 7.8 Hz), 0.92 (d, 3H, J 6.0 Hz), 0.88 (s, 3H), 0.72 (s, 3H). **1c**: 1 H-NMR (CDCl₃, δ_{ppm}), 8.11-7.23 (m, 15H, H-OBz), 5.86(dd, 1H, J_{2′, 3′}, 2.4, J_{3′, 4′} 9.9 Hz H-3′), 5.65 (t, 1H, J 9.9 Hz, H-4′), 5.58(dd, 1H, J_{2'.3}, 2.4, J_{1'.2}, 1.8 Hz H-2), 5.15 (s, 1H, H-1), 4.49 (m, 1H, H-16), 3.63-3.45(m, 3H, H-3 and H-26), 1.33 (d, 3H, $J_{5',6'}$ 6.3 Hz H-6). **1f**: ¹H-NMR (CDCl₃, δ_{ppm}), 8.00-7.33(m, 15H), 5.80(dd, 1H, J_{1', 2'} 8.1, J_{2', 3'} 10.5 Hz, H-2), 5.53(s, 1H, PhCH), 5.32(dd, 1H, J_{2', 3'} 10.5, $J_{3',4'}$ 3.6 Hz , H-3), 4.84 (d, 1H, $J_{1',2'}$ 8.1Hz, H-1), 4.57(d, 1H, $J_{3',4'}$ 3.6Hz, H-4),4.38 (m, 2H, H-16 and H-5), 4.12 (d, 1H, H-26a), 3.62 (m, 2H, H-6), 3.48-3.32 (m, 2H, H-3 and H-26b).0.95(d, 3H, J 6.9Hz),0.78 (d, 3H, J 6.0Hz), 0.72(s, 3H), 0.68(s, 3H). **2b.** ¹H-NMR $(CDCl_3, \delta_{ppm}), 8.11-7.26(m, 20H, H-OBz), 5.97(d, 1H, J_{3',4'}, 3.6 Hz, H-4'), 5.77 (dd, 1H, J_{1',2'}, 1.5 Hz, 1.5 Hz,$ 8.1, J_{2′, 3′} 10.4 Hz, H-2), 5.58(dd, 1H, J_{2′, 3′} 10.4, J_{3′, 4′} 3.6 Hz, H-3), 5.21(d, 1H, J_{5,6} 4.5 Hz H-6), 4.90 (d, 1H, J_{1', 2'} 8.1 Hz, H-1'), 4.67 (dd, 1H, J_{5', 6'a} 63, J_{5', 6'b} 6.3 Hz, H-5'), 4.44-4.36(m, 2H, H-6), 4.32(q, 1H, H-16), 3.57-3.33(m, 3H, H-3 and H-26), 2.18(m, 2H), 0.99(d, 3H, J 5.4 Hz), 0.92 (s, 3H), 0.78(d, 3H, J 6.3Hz), 0.76(s, 3H). **2c** ¹H-NMR (CDCl₃, $\delta_{ppm}),\,8.11\text{--}7.23(m,\,15\text{H},\,\text{H-OBz}),\,5.86(dd,\,1\text{H},\,J_{2',\,3'}\,\,3.6,\,J_{3',\,4'}\,9.7\,\,\text{Hz}\,\,\text{H--3}\,),\,5.68\,(dd,\,1\text{H},\,J_{9.6}\,\,10.8\,\,\text{Hz},\,H_{-4}\,),\,5.61(dd,\,1\text{H},\,J_{2',\,3'}\,\,3.6,\,J_{1',\,2'}\,\,1.8\,\,\text{Hz},\,H_{-2}\,),5.37(d,\,1\text{H},\,J_{5,6}\,\,4.5\,\,\text{Hz}\,\,\text{H--6})$ 5.16(s, 1H, H-1),4.40(m, 1H, H-16), 4.25(m, 1H, H-5'), 3.59-3.38(m, 3H, H-3 and H-26), 1.33(d, J_{5′, 6′} 6.3 Hz H-6).
- 18. Data of compounds **3a** to **3c** were deposited in editorial office of CCL.
- 19. The spectral data of 2a, 2d and 2e were the same as references 14, 15 and 16 reported.

Received 29 April, 2004